Research Article
Tanshinone IIA Regulate Inflammatory Response and Promote Functional Recovery in Rats with Spinal Cord Injury
Bin Lin
,
Aini Lin,
Weiting Chen*
Issue:
Volume 13, Issue 2, April 2024
Pages:
17-22
Received:
1 April 2024
Accepted:
13 April 2024
Published:
29 April 2024
Abstract: Purpose: The treatment of spinal cord injury (SCI) is a clinical challenge. The study attempted to investigate the effects of Tanshinone IIA on SCI in rats. Methods: The SCI model of rat was established based on Allen's animal model. The rats were randomly divided into four groups as follows: Control, Sham, SCI model, SCI + Tanshinone IIA. Rats were administrated with Tanshinone IIA (30mg/kg) respectively daily within one week after establishment of SCI model. Scores of Basso, Beattie, Bresnahan (BBB) was evaluated on the 1st, 3rd, 5th and 7th day after operation. Rats were sacrificed seven days after SCI, and the pathological injury of spinal cord tissue was assessed by HE staining. The levels of inflammatory cytokines (IL-1β and TNF-α) were detected by ELISA. Results: On the 7th day after operation, the BBB score of SCI + Tanshinone IIA group was significantly better than that of SCI group (P<0.01). Compared with SCI group, the pathological changes, neuronal pyknosis, hemorrhage, inflammatory infiltration, and white matter cavity formation in SCI + Tanshinone IIA group were reduced. Compared with SCI group, the level of IL-1 β and TNF-α in SCI+ Tanshinone IIA group were significantly lower (P<0.01). Conclusion: Tanshinone IIA can significantly improve motor function inhibit inflammation and repair spinal cord function after SCI.
Abstract: Purpose: The treatment of spinal cord injury (SCI) is a clinical challenge. The study attempted to investigate the effects of Tanshinone IIA on SCI in rats. Methods: The SCI model of rat was established based on Allen's animal model. The rats were randomly divided into four groups as follows: Control, Sham, SCI model, SCI + Tanshinone IIA. Rats wer...
Show More
Case Report
Efficacy of Combination Therapy with External Human Epidermal Growth Factor and Ebastin in 60 Cases of Eczema
Issue:
Volume 13, Issue 2, April 2024
Pages:
23-28
Received:
16 April 2024
Accepted:
13 May 2024
Published:
30 May 2024
DOI:
10.11648/j.cmr.20241302.12
Downloads:
Views:
Abstract: Objective: The primary aim of this research endeavor was to meticulously evaluate the efficacy and safety profile of integrating external human epidermal growth factor (EGF) with ebastine in the therapeutic management of eczema, Methods: A comprehensive cohort comprising sixty patients clinically diagnosed with eczema and admitted to our esteemed medical facility during the period spanning from June 2020 to June 2022 was meticulously curated for this investigation. Employing a rigorous randomized allocation procedure, the recruited patients were stratified into two distinct groups: the control group and the study group. The control group, serving as the comparative benchmark, underwent treatment with conventional ebastine therapy, whereas the study group was subjected to a novel therapeutic regimen encompassing the combined administration of external human epidermal growth factor and ebastine. Throughout the study duration, each patient's response to treatment was diligently monitored and meticulously documented. Results: Upon comprehensive analysis of the treatment outcomes, it was unequivocally evident that the therapeutic regimen involving the concomitant administration of external human epidermal growth factor and ebastine yielded markedly superior outcomes in comparison to the conventional ebastine monotherapy. Specifically, the study group exhibited an impressively high effective rate of 96.7%, which starkly contrasted with the comparatively modest effective rate of 73.3% observed in the control group (P < 0.05). Moreover, the incidence of adverse reactions in the study group was notably lower, standing at 13.3%, as opposed to the substantially higher incidence rate of 46.7% documented in the control group (P < 0.05). These compelling findings underscore the profound therapeutic potential and favorable safety profile associated with the innovative combination therapy. Conclusions: In light of the compelling evidence gleaned from this meticulously conducted study, it can be unequivocally concluded that the integration of external human epidermal growth factor with ebastine holds immense promise as a novel therapeutic strategy for the effective management of eczema. These findings advocate for the wider adoption and integration of this innovative therapeutic approach into mainstream clinical practice, thereby signifying a pivotal advancement in the armamentarium against this debilitating dermatological ailment.
Abstract: Objective: The primary aim of this research endeavor was to meticulously evaluate the efficacy and safety profile of integrating external human epidermal growth factor (EGF) with ebastine in the therapeutic management of eczema, Methods: A comprehensive cohort comprising sixty patients clinically diagnosed with eczema and admitted to our esteemed m...
Show More
